Treatment utilization and outcomes in patients with mycosis fungoides and Sézary syndrome receiving mogamulizumab in community and academic practice in the United States clinical practice

This retrospective cohort study evaluated adults with mycosis fungoides (MF) or Sezary syndrome (SS) treated with mogamulizumab at community or academic centers (2018-2023). Among 104 patients (MF/SS: 50/54), median (Q1, Q3) time from diagnosis to mogamulizumab was 38.0 (3.0, 12.2) months and median (Q1, Q3) number of prior systemic therapies was 2 (1, 4). Of 99 patients assessed, 68.7% responded, with a median response duration of 11.2 (95% confidence interval [CI]: 7.5, 20.5) months. Median time to next treatment and progression-free survival were 12.3 (95% CI: 7.2, 22.3) and 8.4 (95 CI%: 4.9, 11.9) months, respectively. Selected adverse events (AE) occurred in 94 patients (85.5%) (infection: 44 [40.0%]; infusion reaction: 28 [25.5%]; skin AEs: 79 [71.8%]). Treatment-emergent rash was reported in 18/45 patients (40%). The findings of similar AE rates and treatment outcomes suggest comparable safety and effectiveness in patients treated with mogamulizumab in the community and academic settings.